NXTC

NextCure, Inc.

1.79 USD
+0.06 (+3.47%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

NextCure, Inc. stock is up 46.72% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 4 March’s closed higher than February.

About NextCure, Inc.

NextCure, Inc. engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. NC410, NC762, NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells.